Search
for
Sort by
Research
60-90 / 1000+ results
research Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene
The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research COMPARATIVE EVALUATION OF EFFICACY AND SAFETY OF TOPICAL METHOTREXATE WITH TRETINOIN VERSUS BETAMETHASONE WITH TRETINOIN IN PATIENTS OF ALOPECIA AREATA: A PROSPECTIVE RANDOMIZED DOUBLE-BLIND STUDY
Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research RP-HPLC-Based Stability-Indicating Analytical Method for Concurrent Determination of Finasteride and Tadalafil: Development and Validation
A reliable method was developed to measure Finasteride and Tadalafil together, showing they degrade under certain conditions.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Trazodone associated with Clomiphene a proposal treatment for post finasteride syndrome
The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
research Monilethrix treated with the oral retinoid Ro 10-9359 (Tigason)
Tigason improved hair growth in a boy with monilethrix without side effects.
research Topikal Retinoidler
Tretinoin is used topically to treat acne, skin aging, and various skin conditions.
research Intralesional pentoxifylline injection in localized alopecia areata
Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.
research THU0189 Safety of four treatment regimens in early rheumatoid arthritis
All four treatments for early rheumatoid arthritis had similar safety profiles.
research Tufted hair folliculitis: complete enduring response after treatment with rifampicin
Rifampicin effectively treated tufted hair folliculitis with no relapse after one year.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Trichotillomania Successfully Treated With Risperidone and Naltrexone: A Geriatric Case Report
Trichotillomania was successfully treated with risperidone and naltrexone.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Simultaneous Estimation of Finateride and Tamsulosin Hydrochloride in Pharmaceutical Dosage forms by Uv Spectrophotometric, RP-HPLC and HPTLC Methods.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
research Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report
Antituberculosis drugs can cause severe skin reactions, requiring careful diagnosis and treatment.
research Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
research Itraconazole therapy for recalcitrant dermatophyte infections
Itraconazole helps improve tough skin infections but may not prevent them from coming back.
research Combining 308-monochromatic excimer phototherapy with monthly IM triamcinolone acetonide for the treatment of resistant alopecia totalis
The combination therapy was effective and well-tolerated, especially in young patients.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
Ritlecitinib was generally well tolerated in children with alopecia areata.